Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,113Revenue (TTM) $M38,417Net Margin (%)7.8Altman Z-Score1.1
Enterprise Value $M111,612EPS (TTM) $0.6Operating Margin %13.8Piotroski F-Score7
P/E(ttm)28.8Beneish M-Score-3.0Pre-tax Margin (%)11.6Higher ROA y-yY
Price/Book51.410-y EBITDA Growth Rate %-1.9Quick Ratio0.4Cash flow > EarningsY
Price/Sales2.25-y EBITDA Growth Rate %-8.5Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow14.1y-y EBITDA Growth Rate %114ROA % (ttm)4.0Higher Current Ratio y-yN
Dividend Yield %4.2PEG--ROE % (ttm)230Less Shares Outstanding y-yN
Payout Ratio %169Shares Outstanding M4,958ROIC % (ttm)17.5Gross Margin Increase y-yY

Gurus Latest Trades with GLAXF

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

GLAXF is held by these investors:

GLAXF: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22-15.91view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14-12.49view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29249.72view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$1254.17view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$1432.14view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$1254.17view

Quarterly/Annual Reports about GLAXF:

    News about GLAXF:

    Articles On GuruFocus.com
    GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for Jan 12 2018 
    Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated Jan 08 2018 
    Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Jan 08 2018 
    Paul Stead Joins Adaptimmune as Vice President of Business Development Jan 04 2018 
    GlaxoSmithKline Is a Massive Bargain Dec 30 2017 
    Stocks That Fell to 3-Year Lows in the Week of Dec. 15 Dec 17 2017 
    GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with Dec 12 2017 
    Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T Dec 11 2017 
    GlaxoSmithKline and the Dividend Mirage Dec 05 2017 
    Here's How Walmsley Just Completed a Clean Sweep at GlaxoSmithKline Nov 24 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat